Technical Analysis for BIVI - BioVie Inc.

Grade Last Price % Change Price Change
F 0.64 -0.85% -0.01
BIVI closed down 8.37 percent on Monday, March 18, 2024, on 57 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish -0.90%
180 Bearish Setup Bearish Swing Setup -0.90%
Narrow Range Bar Range Contraction -0.90%
New 52 Week Low Weakness -0.90%
Wide Bands Range Expansion -0.90%
Oversold Stochastic Weakness -0.90%
Stochastic Buy Signal Bullish -9.19%
Narrow Range Bar Range Contraction -9.19%
Wide Bands Range Expansion -9.19%
Oversold Stochastic Weakness -9.19%

   Recent Intraday Alerts

Alert Time
Bearish 180 Entry 9 minutes ago
Fell Below Previous Day's Low 9 minutes ago
New 52 Week Low 9 minutes ago
Up 1% 24 minutes ago
New 52 Week Low about 19 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BioVie Inc. Description

BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of market exclusivity in the US for the designated use(s). It is being investigated as a potential new therapy for patients suffering from ascites, and future development opportunities include hepatorenal syndrome (HRS) and other life-threatening complications of advanced liver cirrhosis. The initial disease target for BIV201 therapy is ascites, which is a serious complication of advanced liver cirrhosis. The Company has completed a Phase 2 clinical trial protocol that is summarized on www.clinicaltrials.gov, trial identifier NCT04112199. The FDA has never approved any drug specifically for treating ascites, and the Company is not aware of any competing drugs in late-stage development for ascites. The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The Company has invented a patent-pending prefilled syringe that has been cleared for use in our upcoming Phase 2 trial subject to certain additional standard analytical tests. This novel BIV201 delivery system is expected to greatly simplify at-home patient treatment and improve patient compliance by enabling easy injection of the liquid concentrate into the IV bag connected to the infusion pump. Room temperature stability has been achieved for 9 months providing an important advantage because, to the best of the Company's knowledge, all other terlipressin products sold globally must be stored under refrigeration. The novel prefilled syringe format also avoids the manual mixing of minute (2 - 4 mg) quantities of terlipressin powder in saline solution, thereby reducing the possibility of dosing errors during reconstitution and improving sterility. BioVie has begun applying for global patent protection for this novel terlipressin delivery system. The Company has also received Orphan Drug designation for the treatment of hepatorenal syndrome (HRS) and has FDA Fast Track status.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Medicine FDA Refrigeration Orphan Drug Hepatology Syringe Infusion Pump Drug Design Digestive Diseases Liver Hepatorenal Syndrome Sterility Treatment Of Hepatorenal Syndrome

Is BIVI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.2799
52 Week Low 0.641
Average Volume 2,832,681
200-Day Moving Average 3.04
50-Day Moving Average 1.08
20-Day Moving Average 1.00
10-Day Moving Average 0.73
Average True Range 0.18
RSI (14) 37.50
ADX 21.41
+DI 41.72
-DI 28.78
Chandelier Exit (Long, 3 ATRs) 2.78
Chandelier Exit (Short, 3 ATRs) 1.17
Upper Bollinger Bands 1.63
Lower Bollinger Band 0.37
Percent B (%b) 0.22
BandWidth 126.29
MACD Line -0.15
MACD Signal Line -0.11
MACD Histogram -0.0384
Fundamentals Value
Market Cap 31.01 Million
Num Shares 48 Million
EPS -1.46
Price-to-Earnings (P/E) Ratio -0.44
Price-to-Sales 0.00
Price-to-Book 7.44
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.75
Resistance 3 (R3) 0.76 0.73 0.73
Resistance 2 (R2) 0.73 0.71 0.73 0.72
Resistance 1 (R1) 0.69 0.69 0.68 0.68 0.72
Pivot Point 0.67 0.67 0.66 0.66 0.67
Support 1 (S1) 0.62 0.64 0.61 0.61 0.57
Support 2 (S2) 0.60 0.62 0.59 0.57
Support 3 (S3) 0.56 0.60 0.56
Support 4 (S4) 0.55